Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.4
Journals
Medicina
Special Issues
Non-motor Disorders in Parkinson’s Disease and Other Parkinsonian Syndromes, 2nd...
share announcement

Non-motor Disorders in Parkinson’s Disease and Other Parkinsonian Syndromes, 2nd Edition

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Neurology".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 2441

Special Issue Editor

Dr. Anastasia Bougea

E-Mail Website
Guest Editor
1st Department of Neurology, Memory & Movement Disorder Clinic, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Interests: Parkinsonian syndromes; dementias and biomarkers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Parkinson’s disease (PD) is the second most common multi-systemic neurodegenerative disorder that is characterized by a broad spectrum of motor and non-motor symptoms (NMS). Atypical Parkinsonism is a less common group of sporadic, neurodegenerative diseases of the central nervous system but more severe than PD. The most common forms are multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and dementia with Lewy bodies (DLB). Neuroanatomically, NMS may be subdivided into cortical manifestations (psychosis and cognitive impairment), basal ganglia symptoms (impulse control disorders, apathy, and restlessness or akathisia), brainstem symptoms (depression, anxiety, and sleep disorders), and peripheral nervous system disturbances (orthostatic hypotension (OH), constipation, pain), and sensory disturbances. NMS is often overlooked by physicians and dismissed by patients, making its management difficult and a major burden for patients and caregivers. Unfortunately, there is very little existing data about NMS, their neurobiology, their potential biomarkers, their monitoring, and their treatment. Moreover, there is growing evidence of accurate monitoring of NMS by wearable sensors for PD. It is, therefore, essential that researchers and practitioners comprehensively address the factors related to NMS in order to improve the quality of life for PD patients.

The aim of the 2nd edition of this Special Issue is to welcome back research articles, opinion/perspective articles, and review articles (narrative reviews, systematic reviews, and meta-analyses), as well as preclinical studies with animal models.

Dr. Anastasia Bougea
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Parkinson’s disease (PD)
  • non-motor symptoms
  • atypical Parkinsonism
  • genetics
  • biomarkers
  • wearable sensors

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

8 pages, 271 KiB  
Article
Immersive Virtual Reality as Computer-Assisted Cognitive–Motor Dual-Task Training in Patients with Parkinson’s Disease
by Lucie Honzíková, Marcela Dąbrowská, Irena Skřinařová, Kristýna Mullerová, Renáta Čecháčková, Eva Augste, Jana Trdá, Šárka Baníková, Michal Filip, David Školoudík, Iva Štefková and Vojtěch Štula
Medicina 2025, 61(2), 248; https://doi.org/10.3390/medicina61020248 - 1 Feb 2025
Viewed by 220
Abstract
Background and Objectives: The aim of this study was to determine the effect of immersive virtual reality used as a short-term multifaceted activity with a focus on motor and cognitive function in patients with Parkinson’s Disease. The sub-objective focused on quality of [...] Read more.
Background and Objectives: The aim of this study was to determine the effect of immersive virtual reality used as a short-term multifaceted activity with a focus on motor and cognitive function in patients with Parkinson’s Disease. The sub-objective focused on quality of life in the study group of patients. Materials and Methods: Nineteen patients (64.2 ± 12.8 years) were included in this study. Inclusion criteria for this study: adult patients in Hoehn and Yahr’s stage 1–3, cooperative, with stable health status, independent and mobile. IVR therapy was performed twice a week for 20 min for one month. Input and output measurements were taken within 14 days of starting or ending therapy. The 10 Meter Walk test was used to examine and assess both comfortable and fast walking, and the Timed Up and Go (TUG) + s dual task was applied to quickly assess the highest possible level of functional mobility. The Berg Balance Scale test (BBS) was used to assess balance with a 14-item balance scale containing specific movement tasks. The standardized Parkinson’s Disease Questionnaire (PDQ-39) was used to assess quality of life. Data were processed in the PAST program using a nonparametric paired Wilcoxon test. The significance level was set at α = 0.05. The value of the r score was used to evaluate the effect size. Results: A significant reduction in the time in the fast walk 10MWT (p = 0.006; r = 0.63) and TUG (p < 0.001; r = 0.80) parameter were found after therapy. Significant improvement in the BBS score was found after applied therapy (p = 0.016; r = 0.55). In the PDQ-39 questionnaire, significant improvements were found in the study group after therapy in the domains of mobility (p = 0.027; r = 0.51) and emotional well-being (p = 0.011; r = 0.58). Conclusions: The results of this study indicate a positive effect of virtual reality therapy on balance and gait, which is also good in terms of reducing the risk of falls in the study group. Therapy also promoted quality of life in the study group. Full article
(This article belongs to the Special Issue Non-motor Disorders in Parkinson’s Disease and Other Parkinsonian Syndromes, 2nd Edition)
12 pages, 983 KiB  
Article
An Artificial Neural Network Predicts Gender Differences of Motor and Non-Motor Symptoms of Patients with Advanced Parkinson’s Disease under Levodopa–Carbidopa Intestinal Gel
by Anastasia Bougea, Tajedin Derikvand and Efthymia Efthimiopoulou
Medicina 2024, 60(6), 873; https://doi.org/10.3390/medicina60060873 - 26 May 2024
Viewed by 1628
Abstract
Background and Objectives: Currently, no tool exists to predict clinical outcomes in patients with advanced Parkinson’s disease (PD) under levodopa–carbidopa intestinal gel (LCIG) treatment. The aim of this study was to develop a novel deep neural network model to predict the clinical [...] Read more.
Background and Objectives: Currently, no tool exists to predict clinical outcomes in patients with advanced Parkinson’s disease (PD) under levodopa–carbidopa intestinal gel (LCIG) treatment. The aim of this study was to develop a novel deep neural network model to predict the clinical outcomes of patients with advanced PD after two years of LCIG therapy. Materials and Methods: This was a longitudinal, 24-month observational study of 59 patients with advanced PD in a multicenter registry under LCIG treatment from September 2019 to September 2021, including 43 movement disorder centers. The data set includes 649 measurements of patients, which make an irregular time series, and they are turned into regular time series during the preprocessing phase. Motor status was assessed with the Unified Parkinson’s Disease Rating Scale (UPDRS) Parts III (off) and IV. The NMS was assessed by the NMS Questionnaire (NMSQ) and the Geriatric Depression Scale (GDS), the quality of life by PDQ-39, and severity by Hoehn and Yahr (HY). Multivariate linear regression, ARIMA, SARIMA, and Long Short-Term Memory–Recurrent NeuralNetwork (LSTM-RNN) models were used. Results: LCIG significantly improved dyskinesia duration and quality of life, with men experiencing a 19% and women a 10% greater improvement, respectively. Multivariate linear regression models showed that UPDRS-III decreased by 1.5 and 4.39 units per one-unit increase in the PDQ-39 and UPDRS-IV indexes, respectively. Although the ARIMA-(2,0,2) model is the best one with AIC criterion 101.8 and validation criteria MAE = 0.25, RMSE = 0.59, and RS = 0.49, it failed to predict PD patients’ features over a long period of time. Among all the time series models, the LSTM-RNN model predicts these clinical characteristics with the highest accuracy (MAE = 0.057, RMSE = 0.079, RS = 0.0053, mean square error = 0.0069). Conclusions: The LSTM-RNN model predicts, with the highest accuracy, gender-dependent clinical outcomes in patients with advanced PD after two years of LCIG therapy. Full article
(This article belongs to the Special Issue Non-motor Disorders in Parkinson’s Disease and Other Parkinsonian Syndromes, 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop